Why is Acasti Pharma, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
7.02%
EBIT to Interest (avg)
-19.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.00
Tax Ratio
25.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
21.67%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.78
EV to EBIT
-1.77
EV to EBITDA
-1.77
EV to Capital Employed
0.72
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.80%
ROE (Latest)
-24.78%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Technical Movement
10What is working for the Company
NET PROFIT(HY)
Higher at USD -4.88 MM
ROCE(HY)
Highest at -16.78%
OPERATING PROFIT(Q)
Highest at USD -3.09 MM
PRE-TAX PROFIT(Q)
Highest at USD -2.88 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Acasti Pharma, Inc.
Operating Profit
Highest at USD -3.09 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -2.88 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Higher at USD -4.88 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales






